Replimune (REPL) has an average rating of hold and mean price target of $10.67, according to analysts polled by FactSet.
What else is happening in Research?
Research
Update: BofA Downgrades Doximity to Underperform From Buy, Cuts Price Target to $20 From $38
(Updates with the analyst's commentary.)BofA Securities downgraded Doximity (DOCS) to underperform rating from buy and cut its price target to $20 from $38.The brokerage attributes the downgrade to "limited clarity" on near-term revenue/margins movement and "execution risks" from the company's pivot to artificial intelligence (AI).While BofA believes Doximity is "making the right strategic investments," the brokerage has "some concerns" over the firm's capability "to grow its current allocations" and to compete in the AI space.Doximity has an average rating of overweight and mean price target of $24.27, according to analysts polled by FactSet.Price: $20.63, Change: $-0.25, Percent Change: -1.20%
$DOCS
Research
BofA Securities Initiates Quantinuum at Buy With $100 Price Target
BofA Securities Initiates Quantinuum at Buy With $100 Price Target
$QNT
Research
BTIG Downgrades Theravance Biopharma to Neutral From Buy
BTIG Downgrades Theravance Biopharma to Neutral From Buy
$TBPH